Immediate Impact
5 from Science/Nature 62 standout
Citing Papers
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2023 Standout
Works of Prodipto Pal being referenced
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors
2021
GermlineBRCAMutations Denote a Clinicopathologic Subset of Prostate Cancer
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Prodipto Pal | 380 | 98 | 242 | 300 | 48 | 930 | |
| Nobuo Hoshi | 272 | 216 | 248 | 346 | 54 | 1.0k | |
| Roger Coleman | 303 | 103 | 264 | 489 | 43 | 1.0k | |
| Quan Li | 203 | 93 | 162 | 527 | 41 | 1.0k | |
| Annette Schneider | 186 | 158 | 199 | 361 | 36 | 1.0k | |
| Matteo Trucco | 376 | 263 | 311 | 347 | 36 | 958 | |
| Christiane Maier | 422 | 60 | 117 | 400 | 32 | 945 | |
| Michael S. Rutenberg | 337 | 89 | 85 | 525 | 53 | 1.1k | |
| Shimiao Zhu | 367 | 122 | 181 | 513 | 38 | 982 | |
| Naoki Nihei | 466 | 257 | 216 | 428 | 45 | 1.0k | |
| Lora K. Hedges | 671 | 88 | 98 | 200 | 24 | 1.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...